- Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum
- Why BTD / RMAT Designations Matter
- Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001
Millions of People Suffer from Sight-Threatening Corneal Endothelial Diseases
Our Cell Therapy Has the Potential to
Restore Their Vision
Company recognized for innovations in clinically validated cell therapy for corneal endothelial dystrophies
Get to know us.
We are a clinical-stage biotech company. We aim to restore vision to all who need it by developing a platform of innovative, accessible, and effective advanced therapies. Our first candidate is a patented cell therapy treatment for corneal endothelial disease.
Latest News
-
Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum
Read More -
Why BTD / RMAT Designations Matter
Read More -
Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001
Read More